Agilent Technologies Acquires Biocare Medical
March 9, 2026
Agilent Technologies entered into a definitive agreement to acquire Biocare Medical, a global provider of clinical and research pathology solutions, for $950 million in an all-cash transaction. The acquisition expands Agilent’s pathology portfolio—particularly in immunohistochemistry (IHC)—and is expected to be accretive to Agilent’s top-line growth rate, margin profile, and non-instrument revenue mix in Year 1.
- Buyers
- Agilent Technologies Inc.
- Targets
- Biocare Medical
- Sellers
- Investor group led by Excellere Partners, GHO Capital Partners LLP
- Industry
- Medical Devices
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Agilent Technologies Acquires BIOVECTRA for $925M
July 22, 2024
Pharmaceuticals
Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.
-
Biogen Acquires Human Immunology Biosciences for up to $1.8B
May 22, 2024
Biotechnology
Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.
-
Agilent Technologies Acquires Avida Biomed
January 4, 2023
Biotechnology
Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.
-
Biocare Medical Acquires Empire Genomics
November 23, 2022
Biotechnology
Biocare Medical, a GHO Capital-backed provider of automated IHC and FISH instrumentation and reagents, has acquired Empire Genomics, a designer and manufacturer of FISH/CISH probes and molecular biomarkers. The deal expands Biocare's molecular portfolio (bringing over one million biomarkers) and adds rapid biomarker development capabilities to accelerate cancer research and diagnostics.
-
GHO Capital and Excellere Partners Invest in Biocare Medical
December 9, 2021
Medical Devices
London-based GHO Capital has invested in Biocare Medical, a California-headquartered developer of immunohistochemistry reagents and diagnostic instrumentation, alongside existing investor Excellere Partners. The capital will be used to accelerate R&D, expand the instrument offering, and support international expansion to capture growing demand for oncology diagnostics.
-
Discovery Life Sciences Acquires QualTek Molecular Laboratories
May 5, 2019
Healthcare Services
Discovery Life Sciences (based in Huntsville, Alabama) has acquired QualTek Molecular Laboratories, a provider of CAP/CLIA-accredited and GLP-capable immunohistochemistry (IHC) laboratories in California and Pennsylvania. The acquisition expands Discovery's histopathology and IHC assay development capabilities and integrates QualTek's services with Discovery's biospecimen, sequencing, flow cytometry and multiomic annotation offerings to accelerate biomarker validation and drug/diagnostic development.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.